Literature DB >> 41540

Bioavailability of temazepam in soft gelatin capsules.

L M Fuccella.   

Abstract

1 Healthy volunteers received single doses of temazepam 30 mg in conventional gelatin capsules, suppositories or in solution. They experienced marked sedation and sleepiness. The onset of sleepiness was prompt after the administration of the solution; this latter showed the fastest absorption and gave the highest peak plasma levels. This observation led to the development of the soft gelatin capsule. 2 To assess bioavailability of the formulation, plasma levels of temazepam were determined in healthy volunteers after single oral administration of soft and hard capsules, and after seven consecutive night-time doses of the soft capsule. Absorption from the soft gelatin capsule was faster and produced earlier and higher peak plasma levels. There were no differences in relative availability. 3 The apparent half-life of temazepam after night-time administration was shorter than after morning administration, but no change was observed between the first and seventh night-time doses.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 41540      PMCID: PMC1429631          DOI: 10.1111/j.1365-2125.1979.tb00452.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  3 in total

1.  Evaluation of the effectiveness of temazepam on the insomnia of patients with neurosis and endogenous depression.

Authors:  C Maggini; M Murri; G Sacchetti
Journal:  Arzneimittelforschung       Date:  1969-10

2.  Study of physiological availability of temazepam in man.

Authors:  L M Fuccella; G Tosolini; E Moro; V Tamassia
Journal:  Int J Clin Pharmacol       Date:  1972-11

3.  Human pharmacokinetics and bioavailability of temazepam administered in soft gelatin capsules.

Authors:  L M Fuccella; G Bolcioni; V Tamassia; L Ferrario; G Tognoni
Journal:  Eur J Clin Pharmacol       Date:  1977-12-16       Impact factor: 2.953

  3 in total
  9 in total

1.  Pharmacokinetic aspects of rectal formulations of temazepam.

Authors:  L M Hanff; W J Rutten
Journal:  Pharm World Sci       Date:  1996-06

Review 2.  Hypnotics. Their place in therapeutics.

Authors:  A N Nicholson
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

Review 3.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

Review 4.  Temazepam: a review of its pharmacological properties and therapeutic efficacy as an hypnotic.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-05       Impact factor: 9.546

5.  Pharmacodynamic correlates of modified absorption: studies with lormetazepam.

Authors:  D M Pierce; R A Franklin; T V Harry; A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

6.  Psycho-social stress, insomnia and temazepam: a sleep laboratory evaluation in a "general practice" sample.

Authors:  M D Beary; J H Lacey; M B Crutchfield; A V Bhat
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 7.  The use of microcomputer-based psychomotor tests for the evaluation of benzodiazepine effects on human performance: a review with emphasis on temazepam.

Authors:  G W Kunsman; J E Manno; B R Manno; C M Kunsman; M A Przekop
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

8.  The neuro-endocrine impact of 3-hydroxy-diazepam (temazepam) in women.

Authors:  M D Beary; J H Lacey; A V Bhat
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  The effects of age and chronic liver disease on the elimination of temazepam.

Authors:  H Ghabrial; P V Desmond; K J Watson; A J Gijsbers; P J Harman; K J Breen; M L Mashford
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.